Arena Pharmaceuticals, Inc. news

   Watch this stock
Showing stories 1 - 10 of about 68   

Articles published

ARNA 3.93 -0.06 (-1.50%)
price chart
Buy Arena Before European Approval Comes Through
Arena Pharmaceutical (NASDAQ:ARNA), a company operating in the healthcare sector, is involved in developing and commercializing drugs that target 'G-protein coupled receptors'.
Arena Pharmaceuticals, Inc. (NASDAQ:ARNA) Surging on Rumors?  HotStocked
3 Reasons to Buy VIVUS  DailyFinance
Related articles »  
Arena Buyout Rumors Are Overblown
What happens when a small pharmaceutical company hitches its wagon to a drug that finally gains FDA approval? The stock runs, and images of dollars raining down upon the smart early investors cloud reality.
Earnings Preview: Arena Pharmaceuticals
Arena Pharmaceuticals (NASDAQ:ARNA) is scheduled to report its Q2 2012 results on Aug. 9, 2012, after the bell. The Street expects an EPS loss of $0.08 and revenue of $7.38 million.
Insider Sales: Arena Pharmaceuticals, VIVUS Inc, Amarin Corporation  Insider Monkey (blog)
Will pill-popping beat obesity?
Related articles »  
A Valuation Model For Arena's Belviq
With Arena Pharmaceuticals' (ARNA) Belviq finally approved, Arena will be transitioning from being a cash-starved biotech into an earnings-generating one.
Related articles »  
The Potential Market For Arena's Belviq
... because the product the company we invest in has real potential. There is a substantial difference between potential market and the real market for any given product.
Related articles »  
5 Bio-Pharma Stocks To Buy Right Here
Biotechnology and drug stocks offer some of the best potential for big gains in the market. The flip side of that proverbial coin, of course, is a great deal of risk.
Related articles »  
Arena: Was This Pharmaceutical Stock a Pump and Dump?
These companies cannot be judged on their balance sheet because future earnings depend on FDA approval and successful sales and marketing.
Related articles »  
Simple Math Showing Why Synergy Pharmaceuticals Is Undervalued
Buying SGYP today after IRWD approval still makes sense just above $5/share. Retail investors have been pounded when trying to play bank-shots off of competitor FDA approvals in recent months.
Related articles »  
Delegate to GOP convention is following family tradition
"Fifty-two years later, I'm following in his footsteps," said Wang's daughter, Arna Souza, on hand this week in Tampa, Fla.
What Slims Down Fastest After Diet Drugs Are Approved by the FDA? Two ...
The latest example of this is Vivus Inc. (VVUS), which has a new obesity-fighting drug called Osymia. Along with Arena Pharmaceuticals' (ARNA) Belviq, it got FDA approval this summer. According to the Associated Press, Jefferies analyst Thomas Wei ...
Related articles »